Management options for established chemotherapy-induced peripheral neuropathy

Deirdre R. Pachman, James C. Watson, Maryam B. Lustberg, Nina Wagner-Johnston, Alexandre Chan, Larry Broadfield, Yin Ting Cheung, Christopher Steer, Dawn J. Storey, Kavita D. Chandwani, Judith Paice, Pascal Jean-Pierre, Jeong Oh, Jayesh Kamath, Marie Fallon, Herwig Strik, Susanne Koeppen, Charles L. Loprinzi

Research output: Contribution to journalArticle

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a variety of chemotherapeutic agents. Clinicians are cognizant of the negative impact of CIPN on cancer treatment outcomes and patients' psychosocial functioning and quality of life. In an attempt to alleviate this problem, clinicians and patients try various therapeutic interventions, despite limited evidence to support efficacy of these treatments. The rationale for such use is mostly based on the evidence for the treatment options in non-CIPN peripheral neuropathy syndromes, as this area is more robustly studied than is CIPN treatment. In this manuscript, we examine the existing evidence for both CIPN and non-CIPN treatments and develop a summary of the best available evidence with the aim of developing a practical approach to the treatment of CIPN, based on available literature and clinical practice experience.

Original languageEnglish (US)
Pages (from-to)2281-2295
Number of pages15
JournalSupportive Care in Cancer
Volume22
Issue number8
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Peripheral Nervous System Diseases
Drug Therapy
Therapeutics
Quality of Life

Keywords

  • Chemotherapy-induced peripheral neuropathy
  • CIPN
  • Neuropathy

ASJC Scopus subject areas

  • Oncology

Cite this

Pachman, D. R., Watson, J. C., Lustberg, M. B., Wagner-Johnston, N., Chan, A., Broadfield, L., ... Loprinzi, C. L. (2014). Management options for established chemotherapy-induced peripheral neuropathy. Supportive Care in Cancer, 22(8), 2281-2295. https://doi.org/10.1007/s00520-014-2289-x

Management options for established chemotherapy-induced peripheral neuropathy. / Pachman, Deirdre R.; Watson, James C.; Lustberg, Maryam B.; Wagner-Johnston, Nina; Chan, Alexandre; Broadfield, Larry; Cheung, Yin Ting; Steer, Christopher; Storey, Dawn J.; Chandwani, Kavita D.; Paice, Judith; Jean-Pierre, Pascal; Oh, Jeong; Kamath, Jayesh; Fallon, Marie; Strik, Herwig; Koeppen, Susanne; Loprinzi, Charles L.

In: Supportive Care in Cancer, Vol. 22, No. 8, 2014, p. 2281-2295.

Research output: Contribution to journalArticle

Pachman, DR, Watson, JC, Lustberg, MB, Wagner-Johnston, N, Chan, A, Broadfield, L, Cheung, YT, Steer, C, Storey, DJ, Chandwani, KD, Paice, J, Jean-Pierre, P, Oh, J, Kamath, J, Fallon, M, Strik, H, Koeppen, S & Loprinzi, CL 2014, 'Management options for established chemotherapy-induced peripheral neuropathy', Supportive Care in Cancer, vol. 22, no. 8, pp. 2281-2295. https://doi.org/10.1007/s00520-014-2289-x
Pachman, Deirdre R. ; Watson, James C. ; Lustberg, Maryam B. ; Wagner-Johnston, Nina ; Chan, Alexandre ; Broadfield, Larry ; Cheung, Yin Ting ; Steer, Christopher ; Storey, Dawn J. ; Chandwani, Kavita D. ; Paice, Judith ; Jean-Pierre, Pascal ; Oh, Jeong ; Kamath, Jayesh ; Fallon, Marie ; Strik, Herwig ; Koeppen, Susanne ; Loprinzi, Charles L. / Management options for established chemotherapy-induced peripheral neuropathy. In: Supportive Care in Cancer. 2014 ; Vol. 22, No. 8. pp. 2281-2295.
@article{89ae65e0143a46378b8c2ff4fee7b588,
title = "Management options for established chemotherapy-induced peripheral neuropathy",
abstract = "Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a variety of chemotherapeutic agents. Clinicians are cognizant of the negative impact of CIPN on cancer treatment outcomes and patients' psychosocial functioning and quality of life. In an attempt to alleviate this problem, clinicians and patients try various therapeutic interventions, despite limited evidence to support efficacy of these treatments. The rationale for such use is mostly based on the evidence for the treatment options in non-CIPN peripheral neuropathy syndromes, as this area is more robustly studied than is CIPN treatment. In this manuscript, we examine the existing evidence for both CIPN and non-CIPN treatments and develop a summary of the best available evidence with the aim of developing a practical approach to the treatment of CIPN, based on available literature and clinical practice experience.",
keywords = "Chemotherapy-induced peripheral neuropathy, CIPN, Neuropathy",
author = "Pachman, {Deirdre R.} and Watson, {James C.} and Lustberg, {Maryam B.} and Nina Wagner-Johnston and Alexandre Chan and Larry Broadfield and Cheung, {Yin Ting} and Christopher Steer and Storey, {Dawn J.} and Chandwani, {Kavita D.} and Judith Paice and Pascal Jean-Pierre and Jeong Oh and Jayesh Kamath and Marie Fallon and Herwig Strik and Susanne Koeppen and Loprinzi, {Charles L.}",
year = "2014",
doi = "10.1007/s00520-014-2289-x",
language = "English (US)",
volume = "22",
pages = "2281--2295",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Management options for established chemotherapy-induced peripheral neuropathy

AU - Pachman, Deirdre R.

AU - Watson, James C.

AU - Lustberg, Maryam B.

AU - Wagner-Johnston, Nina

AU - Chan, Alexandre

AU - Broadfield, Larry

AU - Cheung, Yin Ting

AU - Steer, Christopher

AU - Storey, Dawn J.

AU - Chandwani, Kavita D.

AU - Paice, Judith

AU - Jean-Pierre, Pascal

AU - Oh, Jeong

AU - Kamath, Jayesh

AU - Fallon, Marie

AU - Strik, Herwig

AU - Koeppen, Susanne

AU - Loprinzi, Charles L.

PY - 2014

Y1 - 2014

N2 - Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a variety of chemotherapeutic agents. Clinicians are cognizant of the negative impact of CIPN on cancer treatment outcomes and patients' psychosocial functioning and quality of life. In an attempt to alleviate this problem, clinicians and patients try various therapeutic interventions, despite limited evidence to support efficacy of these treatments. The rationale for such use is mostly based on the evidence for the treatment options in non-CIPN peripheral neuropathy syndromes, as this area is more robustly studied than is CIPN treatment. In this manuscript, we examine the existing evidence for both CIPN and non-CIPN treatments and develop a summary of the best available evidence with the aim of developing a practical approach to the treatment of CIPN, based on available literature and clinical practice experience.

AB - Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a variety of chemotherapeutic agents. Clinicians are cognizant of the negative impact of CIPN on cancer treatment outcomes and patients' psychosocial functioning and quality of life. In an attempt to alleviate this problem, clinicians and patients try various therapeutic interventions, despite limited evidence to support efficacy of these treatments. The rationale for such use is mostly based on the evidence for the treatment options in non-CIPN peripheral neuropathy syndromes, as this area is more robustly studied than is CIPN treatment. In this manuscript, we examine the existing evidence for both CIPN and non-CIPN treatments and develop a summary of the best available evidence with the aim of developing a practical approach to the treatment of CIPN, based on available literature and clinical practice experience.

KW - Chemotherapy-induced peripheral neuropathy

KW - CIPN

KW - Neuropathy

UR - http://www.scopus.com/inward/record.url?scp=84905115124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905115124&partnerID=8YFLogxK

U2 - 10.1007/s00520-014-2289-x

DO - 10.1007/s00520-014-2289-x

M3 - Article

C2 - 24879391

AN - SCOPUS:84905115124

VL - 22

SP - 2281

EP - 2295

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 8

ER -